Back to results
US 2022/0064303 A1Published application
Anti-CTLA-4 Binding Proteins and Methods of Use Thereof
AssigneeGigaGen, Inc.
InventorsDavid Scott Johnson, Adam Shultz Adler, Rena Aviva Mizrahi, Yoong Wearn Lim, Michael Asensio, Erica Lyn Stone
Life of this patent
Estimating the term…
Abstract
Provided herein are antigen-binding proteins (ABPs) that selectively bind to CTLA-4 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
Claims23
An isolated antigen binding protein (ABP) that specifically binds a human cytotoxic T-lymphocyte associated protein 4 (CTLA-4), comprising:
- (a) a CDR3-L having a sequence selected from SEQ ID NOS:
- 3001-3028 and a CDR3-H having a sequence selected from SEQ ID NOS:
- 6001-6028;
- or
- (b) a CDR3-L having a sequence selected from SEQ ID NOS:
- 9984-10479 and a CDR3-H having a sequence selected from SEQ ID NOS:
- 11472-11967;
- or
- (c) a CDR3-L having a sequence of the CD3-L of any one of the clones in the library deposited under ATCC Accession No. PTA-125512 and a CDR3-L having a sequence of the CD3-L of any one of the clones in the library deposited under ATCC Accession No. PTA-125512.
6 more elements
The ABP of any of the above claims, wherein the ABP binds human CTLA-4 with a KD of less than 500 nM, as measured by surface plasmon resonance.
Dependencies are inferred from the claim text.